Regeneron (REGN) Stock
NASDAQ · REGN
798.17
Fundamentals
Market cap
$80.80B
Price / Earnings ratio
18.7x
Price / Sales ratio
5.2x
Price / Book ratio
2.5x
Return on assets
0.1%
Ex-Dividend date
18 Aug 2026
Last payment date
N/A
Dividend amount
$0.94
Dividend yield
0.5%
Debt / Equity ratio
N/A
Latest news
About Regeneron
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
SectorHealthcare
IndustryBiotechnology
Employees15,410
CEODr. Leonard S. Schleifer M.D., Ph.D.
IPO DateApr 2, 1991
HeadquartersTarrytown, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 1953 |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 1960 |
| Mr. Christopher R. Fenimore CPA | Executive VP of Finance & CFO | 1971 |
| Mr. Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary | 1959 |
| Dr. Andrew J. Murphy Ph.D. | Executive VP of Research & Co-Chief Scientific Officer | 1958 |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 1973 |
| Mr. Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations | — |
| Mr. Ryan Steinberger | Executive VP, Chief Digital & Technology Officer | — |
| Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | — |
| Ms. Melissa Lozner | Senior VP & Chief Compliance Officer | — |
Fundamentals
Valuation
Market cap$80.80B
Price-to-sales ratio5.20
Price-to-book value2.55
Price-earnings ratio18.70
Return on Equity14.00%
Return on Sales0.35%
Return on Assets0.11%
PEG ratio1.27
Earnings Per Share
Earnings Per Share$41.94
Income Statement
Average volume701,460
EBITDA$5.74B
1 year high (52w)$859.34
1 year low (52w)$541.00
Dividend
Ex dividend date18 Aug 2026
Dividend amount$0.94
Dividend yield0.46%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



